留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

AJCC第8版乳腺癌预后分期重大更新及临床意义

周斌 辛灵 程元甲 刘倩 徐玲 叶京明 段学宁 刘荫华

周斌, 辛灵, 程元甲, 刘倩, 徐玲, 叶京明, 段学宁, 刘荫华. AJCC第8版乳腺癌预后分期重大更新及临床意义[J]. 协和医学杂志, 2017, 8(4-5): 235-238. doi: 10.3969/j.issn.1674-9081.2017.05.008
引用本文: 周斌, 辛灵, 程元甲, 刘倩, 徐玲, 叶京明, 段学宁, 刘荫华. AJCC第8版乳腺癌预后分期重大更新及临床意义[J]. 协和医学杂志, 2017, 8(4-5): 235-238. doi: 10.3969/j.issn.1674-9081.2017.05.008
Bin ZHOU, Ling XIN, Yuan-jia CHENG, Qian LIU, Ling XU, Jing-ming YE, Xue-ning DUAN, Yin-hua LIU. Critical Updates and Clinical Significance of the 8th Edition of AJCC Breast Cancer Prognostic Staging System[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 235-238. doi: 10.3969/j.issn.1674-9081.2017.05.008
Citation: Bin ZHOU, Ling XIN, Yuan-jia CHENG, Qian LIU, Ling XU, Jing-ming YE, Xue-ning DUAN, Yin-hua LIU. Critical Updates and Clinical Significance of the 8th Edition of AJCC Breast Cancer Prognostic Staging System[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 235-238. doi: 10.3969/j.issn.1674-9081.2017.05.008

AJCC第8版乳腺癌预后分期重大更新及临床意义

doi: 10.3969/j.issn.1674-9081.2017.05.008
基金项目: 

首都医学发展科研基金资助项目 2009-1011

首都临床特色应用研究资助项目 Z131107002213007

国家重点研发计划精准医学研究重点专项项目 2016YFC0901300

详细信息
    通讯作者:

    刘荫华  电话:010-83575053,E-mail:liuyinhua@medmail.com.cn

  • 中图分类号: R737.9

Critical Updates and Clinical Significance of the 8th Edition of AJCC Breast Cancer Prognostic Staging System

More Information
  • 摘要: 随着肿瘤相关研究的深入以及基因检测技术在临床应用水平的进步, 肿瘤综合诊治理念已经在细化解剖学分期、精确掌握宏观肿瘤负荷的基础上跨越至分析肿瘤生物学特性、研发靶向治疗药物的新阶段。美国癌症联合会(American Joint Committee on Cancer, AJCC)第8版乳腺癌分期系统专家委员会依据雌激素受体(estrogen receptor, ER)、孕激素受体(progesterone receptor, PR)、人类表皮生长因子受体-2(human epidermal growth factor receptor-2, HER-2)及组织学分级4项生物标志物及多基因检测信息, 首次建立了全新的乳腺癌预后分期评价系统。其优先采用预后分期系统进行评价的临床推荐原则, 将成为人类与癌症抗争史上重大的革命性事件。癌症分期体系从宏观解剖学到微观病理学, 并逐渐加入多基因检测信息, 标志着肿瘤治疗从群体治疗到分类治疗的进步, 并推动乳腺癌诊治进入个体化时代。
  • [1] Giuliano AE, Connolly JL, Edge SB, et al. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual[J]. CA Cancer J Clin, 2017. doi:10.3322/caac.21393.[Epub ahead of print]
    [2] Singletary SE, Connolly JL. Breast cancer staging:working with the sixth edition of the AJCC Cancer Staging Manual[J]. CA Cancer J Clin, 2006, 56:37-47. doi:  10.3322/canjclin.56.1.37
    [3] 周斌, 季科, 辛灵, 等.美国肿瘤联合会乳腺癌分期系统(第8版)更新内容介绍及解读[J].中国实用外科杂志, 2017, (1):10-14. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgsywkzz201701004
    [4] Amin MB, Edge S, Greene FL, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York:Springer, 2016:589-628.
    [5] Mcguire WL. Hormone receptors:their role in predicting prognosis and response to endocrine therapy[J]. Semin Oncol, 1978, 5:428-433. http://europepmc.org/abstract/MED/734443
    [6] Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis:a prospective cohort of breast cancer patients[J]. Breast Cancer Res, 2007, 9:R6. doi:  10.1186/bcr1639
    [7] Purdie CA, Quinlan P, Jordan LB, et al. Progesterone receptor expression is an independent prognostic variable in early breast cancer:a population-based study[J]. Br J Cancer, 2014, 110:565-572. doi:  10.1038/bjc.2013.756
    [8] Ross JS, Slodkowska EA, Symmans WF, et al. The HER-2 receptor and breast cancer:ten years of targeted anti-HER-2 therapy and personalized medicine[J]. Oncologist, 2009, 14:320-368. doi:  10.1634/theoncologist.2008-0230
    [9] Yarden Y. Biology of HER2 and its importance in breast cancer[J]. Oncology, 2001, 61:1-13. http://www.ncbi.nlm.nih.gov/pubmed/11694782
    [10] Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J]. J Clin Oncol, 2007, 25:118-145. http://cn.bing.com/academic/profile?id=d6e2a4e0ba49fdc1c2c8878676f5fe6d&encoded=0&v=paper_preview&mkt=zh-cn
    [11] Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol, 2013, 31:3997-4013. doi:  10.1200/JCO.2013.50.9984
    [12] Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years[J]. Br J Cancer, 1957, 11:359-377. doi:  10.1038/bjc.1957.43
    [13] Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer:experience from a large study with long-term follow-up[J]. Histopathology, 1991, 19:403-410. doi:  10.1111/j.1365-2559.1991.tb00229.x
    [14] Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights:international expert consensus on the primary therapy of early breast cancer 2005[J]. Ann Oncol, 2005, 16:1569-1583. doi:  10.1093/annonc/mdi326
    [15] Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise:highlights of the international expert consensus on the primary therapy of early breast cancer 2007[J]. Ann Oncol, 2007, 18:1133-1144. doi:  10.1093/annonc/mdm271
    [16] Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011[J]. Ann Oncol, 2011, 22:1736-1747. doi:  10.1093/annonc/mdr304
    [17] Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013[J]. Ann Oncol, 2013, 24:2206-2223. doi:  10.1093/annonc/mdt303
    [18] Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer:St Gallen international expert consensus on the primary therapy of early breast cancer 2015[J]. Ann Oncol, 2015, 26:1533-1546. doi:  10.1093/annonc/mdv221
    [19] 叶青, 江泽飞.三阴性乳腺癌精准治疗的机遇[J].中国肿瘤临床, 2016, (24):1074-1077. doi:  10.3969/j.issn.1000-8179.2016.24.048
    [20] Matsen CB, Neumayer LA. Breast cancer:a review for the general surgeon[J]. JAMA Surg, 2013, 148:971-979. doi:  10.1001/jamasurg.2013.3393
    [21] Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual:continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging[J]. CA Cancer J Clin, 2017, 67:93-99. doi:  10.3322/caac.21388
  • 加载中
计量
  • 文章访问数:  63
  • HTML全文浏览量:  45
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-05-12
  • 刊出日期:  2017-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!